Forerunner Ventures

Few firms have shaped the consumer health category as visibly as Forerunner Ventures, the San Francisco fund whose name appears on cap tables of Hims & Hers, Oura, Headway, and Prenuvo. Founded by Kirsten Green and now stewarding roughly $3 billion in assets, Forerunner has spent more than a decade arguing that healthcare is, at its core, a consumer category that has been mispriced as a medical one. The thesis is unfussy: people pay attention to their bodies, their minds, and their longevity in the same ways they pay attention to other meaningful purchases, and the founders who can earn that attention will build the next generation of brands. For physician-founders who think in terms of clinical workflow first, Forerunner is a different kind of partner. They start with the user.

The investment thesis at Forerunner is built around behavioral shifts among consumers, not regulatory or reimbursement tailwinds. Across wellness and consumer health, digital health, and mental and behavioral health, the firm tends to back companies that look more like brands than like clinics, even when there is licensed care delivery underneath. They have backed direct-to-consumer telehealth platforms that make pharmacy access feel like e-commerce, biometric wearables that compete on industrial design as much as accuracy, mental health marketplaces that win on supply density and matching quality, and preventative imaging services positioned as luxury wellness rather than radiology. The pattern across the portfolio is the willingness to fund companies that lead with consumer demand and let the clinical, regulatory, or reimbursement infrastructure follow. Founders should expect questions about brand, retention curves, and unit economics long before they get questions about clinical evidence or payer strategy. Forerunner is comfortable with the position that great consumer companies pull the rest of healthcare toward them.

The portfolio reads like a tour of the most-watched consumer health companies of the past decade. Hims & Hers, now public, established that telehealth could be a marketing-led business and that prescription categories long stigmatized in primary care could be normalized through brand. Oura turned a sleep ring into a recurring-revenue lifestyle product and a credible biometric platform. Headway built one of the more durable mental health marketplaces by solving the insurance friction that had kept therapists out of network. Prenuvo, the whole-body MRI company, has helped make preventative imaging a mainstream consumer purchase rather than a referred procedure. The pattern across these names is clear: each company sits at the boundary between healthcare and consumer culture, each leads with a brand thesis, and each was capable of growing without waiting for institutional adoption.

Forerunner invests at Pre-Seed, Seed, and Series A, with check sizes in the $1 million to $5 million range typical of their early entries, though they meaningfully increase ownership in subsequent rounds for companies they believe in. The capital stack positioning is that of a thesis-driven early-stage lead or co-lead, with enough conviction and reputation to anchor a round and enough capital to follow on through at least the Series B. Founders raising larger seed extensions or pre-empted Series A rounds will find Forerunner price-sensitive but willing to move quickly when the consumer thesis is sharp. They are not the right fund for a clinical-first founder who needs a strategic check from a payer, a health system, or a pharma partner. They are also not a passive co-investor; if Forerunner is in the round, they want to be material to the cap table and to the brand decisions that follow.

Kirsten Green remains the public face and lead investor of the firm and has been one of the most cited consumer investors of the last decade. The broader team has built out healthcare and consumer specialists who source and diligence in the categories the firm has historically owned. Decision-making is partner-led and conviction-driven; Forerunner is known for forming a view quickly and acting on it. For founders, that means meetings move faster than the median Sand Hill experience, but the bar on the consumer thesis is correspondingly higher. References tend to come from existing portfolio CEOs and from the consumer brand operators in Forerunner’s orbit.

The most reliable path into Forerunner is a warm introduction from a portfolio founder, particularly one whose company sits in an adjacent consumer health category. Failing that, introductions from consumer-brand operators, agency principals, or specialist healthcare bankers who have transacted with the firm tend to land. Cold outreach is read but rarely converted; the firm has historically preferred founder networks. When you do get the meeting, lead with the consumer insight, not the clinical model. Show the audience, the brand, the retention, and the cost of acquisition before you show the regulatory architecture. Founders who try to win Forerunner on the strength of their clinical credentials alone tend to leave wondering why the room felt cooler than expected.

Approach Forerunner when you have a defensible consumer wedge in healthcare and the early evidence that real users will pay, return, and refer. Do not approach when you are early in clinical validation but have no consumer traction, when your business depends entirely on payer contracts that have not yet been signed, or when you are looking for a passive check rather than a brand-forward partner. Forerunner is an excellent fit for the founder who believes healthcare is being remade by consumer preferences, and a poor fit for the founder who believes consumers are downstream of the institutions that pay for them.